|[back to articles]|
|Aluminum in antiperspirants linked to breast cancer ?|
|Sep 24, 2007|
|Adverse Events / Health Hazards > Chemical Poisoning|
Aluminum in antiperspirants linked to breast cancer ?
Aluminum, a common ingredient added to antiperspirants to stop skin sweating, may be linked to breast cancer, a study by British scientists found.
The researchers tested breast samples from 17 breast-cancer patients who had undergone mastectomies. The women who used antiperspirants had deposits of aluminum in their outer breast tissue. Concentrations of aluminum were higher in the tissue closest to the underarm than in the central breast.
Aluminum is not normally found in the human body, and the researchers believe the metal is being absorbed from antiperspirant sprays and roll-ons.
Animal studies have found that aluminum can cause cancer, and the British researcher who led this study, Dr. Chris Exley from Keele University, has also suggested that the aluminum content of sunscreens could increase users' risk of skin cancer and Alzheimer's disease.
Further studies are needed to determine if the aluminum came from antiperspirants and whether it contributed to breast cancer.
The director-general of the Cosmetic, Toiletry & Perfumery Association said they do not believe that the aluminum in antiperspirants is absorbed by the body.
Journal of Inorganic Biochemistry November 2007 (This study is not yet published)
Comment: Government regulators need to explain why they allowed Merck to use a potentially reactive aluminum containing placebo as a control for most trial participants, rather than a non-reactive saline solution placebo. A reactive placebo can artificially increase the appearance of safety of an experimental drug or vaccine in a clinical trial. Gardasil contains 225 mcg of aluminum and, although aluminum adjuvants have been used in vaccines for decades, they were never tested for safety in clinical trials. Merck and the FDA did not disclose how much aluminum was in the placebo.
604 818 5448
1. Merck & amp; Co., Inc. 2006. Gardasil [Quadrivalent Human Papillomavirus Types 6,11,16,18) Recombinant Vaccine] product insert. Table 6.
2. Food and Drug Administration. May 18, 2006. FDA Background Document for Vaccines and Related Biological Products Advisory Committee: Gardasil HPV Quadrivalent Vaccine.
|[back to articles]|